Evidence map›Paper›PMID 39773913›Full record

ArticleJCI insight2025

Metabolic fitness of NAC1-deficient Tregs in the tumor microenvironment fuels tumor growth.

Anil Kumar, Jugal Kishore Das, Hao-Yun Peng, Liqing Wang, Darby Jane Ballard, Yijie Ren, Xiaofang Xiong, Xingcong Ren, Jin-Ming Yang, Paul de Figueiredo and 1 more

Abstract read
In one paragraph

Article in JCI insight, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Anil KumarDepartment of Microbial Pathogenesis and Immunology, Texas A&M University Health Science Center, Bryan, Texas, USA.
Jugal Kishore DasDepartment of Microbial Pathogenesis and Immunology, Texas A&M University Health Science Center, Bryan, Texas, USA.
Hao-Yun PengDepartment of Microbial Pathogenesis and Immunology, Texas A&M University Health Science Center, Bryan, Texas, USA.
Liqing WangDepartment of Microbial Pathogenesis and Immunology, Texas A&M University Health Science Center, Bryan, Texas, USA.
Darby Jane BallardDepartment of Microbial Pathogenesis and Immunology, Texas A&M University Health Science Center, Bryan, Texas, USA.
Yijie RenDepartment of Microbial Pathogenesis and Immunology, Texas A&M University Health Science Center, Bryan, Texas, USA.
Xiaofang XiongDepartment of Microbial Pathogenesis and Immunology, Texas A&M University Health Science Center, Bryan, Texas, USA.
Xingcong RenDepartment of Toxicology and Cancer Biology, Department of Pharmacology and Nutritional Science, and Markey Cancer Center, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Jin-Ming YangDepartment of Toxicology and Cancer Biology, Department of Pharmacology and Nutritional Science, and Markey Cancer Center, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Paul de FigueiredoDepartment of Molecular Microbiology and Immunology, University of Missouri School of Medicine, Columbia, Missouri, USA.
Jianxun SongDepartment of Microbial Pathogenesis and Immunology, Texas A&M University Health Science Center, Bryan, Texas, USA.

Funding

Nucleus Accumbens-Associated Protein-1 in Melanoma ImmunotherapyR01CA221867 · NCI · UNIVERSITY OF KENTUCKY · PI SONG, JIANXUN JIM, YANG, JIN-MING · 2018 to 2023
$2.8M
Combating melanoma with an attenuated bacterial therapeuticR01CA273002 · NCI · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI Jianxun Jim Song · 2023 to 2026
$1.8M
Combating chronic neuroinflammatory disorders by targeting NAC1R21AI167793 · NIAID · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI SONG, JIANXUN JIM · 2022 to 2023
$413k
NCI NIH HHS R01 CA221867NCI NIH HHS R01 CA273002NIAID NIH HHS R21 AI167793
6 · The paper itself

Abstract

The nucleus accumbens-associated protein 1 (NAC1) has recently emerged as a pivotal factor in oncogenesis by promoting glycolysis. Deletion of NAC1 in regulatory T cells (Tregs) has been shown to enhance FoxP3 stability, a suppressor of glycolysis. This study delves into the intriguing dual role of NAC1, uncovering that Treg-specific deletion of NAC1 fosters metabolic fitness in Tregs, thereby promoting tumorigenesis. Our results unveil that NAC1-deficient Tregs exhibited prolonged survival and heightened function, particularly in acidic environments. Mechanistically, we find that NAC1-deficient Tregs adapted to adverse conditions by upregulating FoxP3 expression, engaging in CD36-mediated lipid metabolism, and enhancing peroxisome proliferator-activated receptor gamma coactivator 1-alpha-regulated mitochondrial function. In mouse tumor xenograft models, NAC1-deficient mice demonstrated increased susceptibility to tumor growth. Notably, Tregs lacking NAC1 not only displayed elevated lipid metabolism and mitochondrial fitness but also exhibited enhanced tumoral infiltration. Adoptive Treg transfer experiments further underscored the supportive role of NAC1-deficient Tregs in tumor growth. These findings suggest that modulating NAC1 expression in FoxP3+ Tregs could serve as a promising approach to augment antitumor immunity. Understanding the intricate interplay between NAC1 and Tregs opens avenues for potential therapeutic strategies targeting the tumor microenvironment.

Indexed as

NeoplasmsRepressor ProteinsT-Lymphocytes, RegulatoryTumor MicroenvironmentAnimalsCarcinogenesisFemaleForkhead Transcription FactorsGlycolysisHumansLipid MetabolismMiceMice, KnockoutMitochondriaPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaForkhead Transcription FactorsFoxp3 protein, mousePeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaRepressor ProteinsWhn proteinCancerImmunology

Identifiers

PMID39773913
PMCPMC11949012

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.